In part 3 of a Spotlight special series on the role of new weight loss medicines like Ozempic in South Africa, we ask what these breakthrough jabs might mean for people living with HIV in the country. There is some tantalising early research on potential benefits, but also many uncertainties. Catherine Tomlinson reports.
Obesity is a public health crisis in South Africa, similar to HIV in the late 1990s, Dr Nomathemba Chandiwana tells Spotlight on the sidelines of the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. She also presented research that found lifestyle behaviour changes had a limited effect on reversing weight gain in people living with HIV.
Long-acting injections have been successfully used as contraception and more recently HIV prevention. Now researchers are exploring whether similar long-acting injections could be used for the prevention and treatment of tuberculosis. Tiyese Jeranji reports.
Broadly neutralising antibodies (bnAbs) are one of the most active and exciting areas in HIV research. Last year Spotlight reported on a “proof of concept” study showing that a specific bnAb can successfully prevent infection with certain strains of HIV. Now, we also have intriguing findings suggesting that bnAbs may have a role to play in the treatment of HIV in children. Elri Voigt reports.
HIV and ageing were one of the hot topics at the recently held Conference on Retroviruses and Opportunistic Infections. Elri Voigt reports.
Even though the rate of new HIV infections in young women and adolescent girls remains stubbornly high, provision and uptake of pills that can prevent HIV infection have generally been slow and lagging. One potential solution presented at the recent Conference on Retroviruses and Opportunistic Infections is to provide the pills at schools. Tiyese Jeranji reports.
